Fabrice Andre, MD, PhD

Fabrice Andr&eacute;, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.

One factor for platinum treatments includes the presence of

mutations. If a patient presents a germline mutation for either

, a platinum agent such as cisplatin or carboplatin can be used in the frontline setting, according to the results of the TNT trial. However, for individuals that do not show signs of these mutations, platinum agents should not be used in the first-line setting.

Videos

Fabrice Andr&eacute;, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.&nbsp;

Using Platinum Agents in Different Settings of TNBC

Fabrice Andre, MD, PhD, Research Director, Head of INSERM Unit U981, Institut National des Sciences et de la Recherche M&eacute;dicale, Associate Professor, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France, gives an overview of targets in triple-negative breast cancer (TNBC).

With the current vision of targets in breast cancer (genetic alterations located on a kinase, there are no targets in TNBC, Andre says. As this is a very specific view of what to target, there is no clinical research to validate any other way.

Andre believes that immunotherapies, modulation of DNA repair, modulation of kinases, and a combination of a kinase inhibitor and modulators of DNA repair are all interesting areas that deserve further analysis.

There is no target in TNBC with the current vision of breast cancer

In TNBC, immunotherapies, modulation of DNA repair, and modulation of kinases are all interesting areas to be explored further

Fabrice Andre, MD, PhD, says that there are no targets in triple-negative breast cancer in accordance with the current vision of the disease.

Fabrice Andre, MD, PhD | Authors

Articles

Using Platinum Agents in Different Settings of TNBC

Targets in Triple-Negative Breast Cancer